Point of Care Diagnostics Market Size and Forecast 2025–2033

The global Point of Care (PoC) Diagnostics Market is entering a dynamic phase of expansion, fueled by the demand for rapid, accessible, and patient-centric testing solutions. The market, valued at US$ 50.08 billion in 2024, is projected to reach approximately US$ 105.22 billion by 2033, reflecting a strong CAGR of 8,60% from 2025 to 2033.

This robust growth trajectory is driven by rising infectious disease prevalence, increasing chronic disease burdens, healthcare decentralization, and rapid technological innovation. As healthcare systems move toward faster decision-making and personalized medicine, point-of-care diagnostics are becoming indispensable tools across hospitals, clinics, pharmacies, and even home settings.

What is Point of Care Diagnostics?

Point of Care diagnostics refers to medical testing conducted at or near the site of patient care, rather than in centralized laboratories. These tests provide near-instant results, allowing healthcare providers to make timely clinical decisions.

Applications range from simple blood glucose monitoring to advanced molecular diagnostics capable of detecting infectious pathogens, cardiac markers, and genetic conditions.

Key advantages include:

·        Rapid turnaround time

·        Reduced need for centralized labs

·        Improved patient management

·        Enhanced emergency response capabilities

·        Greater accessibility in remote or underserved regions

The COVID-19 pandemic highlighted the importance of decentralized diagnostic solutions. Rapid antigen and molecular testing became critical in managing outbreaks and controlling disease spread. This shift has permanently reshaped healthcare delivery models, embedding PoC testing as a core component of modern medical practice.

Download Free Sample Report:https://www.renub.com/request-sample-page.php?gturl=point-of-care-diagnostics-market-key-players-analysis-p.php

Key Growth Drivers

1. Rising Prevalence of Infectious and Chronic Diseases

The increasing global burden of infectious diseases, respiratory conditions, diabetes, cardiovascular disorders, and metabolic diseases continues to drive demand for rapid diagnostic solutions.

Point-of-care tests are particularly valuable in infectious disease management, enabling early detection and reducing transmission risks. Additionally, chronic disease monitoring through PoC devices improves long-term patient outcomes by supporting proactive care.

2. Technological Advancements and Miniaturization

Innovation in microfluidics, biosensors, molecular diagnostics, and digital health integration has significantly enhanced device performance. Miniaturization has enabled portable, easy-to-use, and cost-effective systems without compromising accuracy.

In November 2023, F. Hoffmann-La Roche Ltd launched the LightCycler® PRO System, expanding its molecular PCR portfolio and bridging translational research with in-vitro diagnostics.

Similarly, in December 2023, Thermo Fisher Scientific Inc. introduced the KingFisher Apex Dx instrument and MagMAX Dx Viral/Pathogen NA Isolation Kit, strengthening automated nucleic acid purification for diagnostic laboratories.

These advancements signal a clear industry shift toward faster, more accurate, and integrated testing platforms.

3. Growing Demand for Patient-Centered Care

Healthcare systems are increasingly focusing on convenience and accessibility. Patients and providers prefer testing methods that minimize wait times and hospital visits.

Point-of-care diagnostics align perfectly with personalized medicine strategies by enabling:

·        Real-time treatment adjustments

·        Faster emergency interventions

·        Improved monitoring in outpatient settings

As healthcare becomes more decentralized, PoC devices are expected to become mainstream across pharmacies, home healthcare, and mobile clinics.

Leading Companies in the Point of Care Diagnostics Market

Sysmex Corporation

Founded in 1968 and headquartered in Japan, Sysmex specializes in diagnostic instruments, reagents, and laboratory information systems. Its expertise spans hematology, hemostasis, and urinalysis analyzers. With R& D facilities across multiple continents, Sysmex maintains a strong global presence and innovation-driven growth model.

Abbott Laboratories

Established in 1888, Abbott is a global healthcare leader offering point-of-care systems, rapid diagnostic tests, cardiovascular devices, and laboratory automation solutions. Its broad distribution network spans North America, Europe, Asia-Pacific, Latin America, and Africa.

Abbott’s strength lies in its ability to integrate diagnostics, medical devices, and digital health solutions into comprehensive care ecosystems.

Becton, Dickinson and Company

Founded in 1897, BD develops and manufactures medical supplies, laboratory equipment, and diagnostic products. Its molecular diagnostic systems and laboratory automation technologies support both centralized and decentralized testing.

BD’s global manufacturing footprint enhances scalability and reliability in supply chain management.

Danaher Corporation

Danaher operates across biotechnology and diagnostic sectors, delivering advanced research instruments and diagnostic systems. Its diversified portfolio supports pharmaceutical companies, healthcare institutions, and research laboratories worldwide.

QuidelOrtho Corporation

Originally founded as Quidel, the company focuses on rapid immunoassays and molecular diagnostic solutions. Its innovative platforms support timely disease detection, particularly in respiratory and infectious disease testing.

SWOT Analysis Highlights

Bio-Rad Laboratories Inc.

Strength: Robust R& D and trusted brand reputation.
Bio-Rad combines regulatory expertise with scalable manufacturing capabilities, enabling efficient commercialization of clinically validated PoC solutions.

QIAGEN N.V.

Strength: Integrated sample-to-result molecular platforms.
QIAGEN’s systems integrate nucleic acid extraction, amplification, and detection, positioning it as a leader in decentralized molecular diagnostics.

Recent Developments

In September 2025, bioMérieux S.A. partnered with Altesa BioSciences to deploy the BIOFIRE® SPOTFIRE® respiratory solution for a Phase 2B clinical trial in the United States. This collaboration highlights the growing integration of PoC diagnostics in clinical research.

In October 2025, Siemens Healthineers AG signed a research collaboration with the National University Hospital in Singapore to enhance diagnostic solutions for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), demonstrating the expanding role of PoC platforms beyond infectious diseases.

Sustainability Initiatives

EKF Diagnostics Holdings plc.

EKF integrates sustainability into manufacturing by reducing carbon emissions, minimizing waste, and sourcing materials responsibly. The company also invests in early detection technologies that contribute to sustainable health outcomes.

Nova Biomedical

Nova Biomedical emphasizes lean manufacturing, energy conservation, and environmentally responsible product design. Its long-lasting diagnostic systems align innovation with ecological stewardship.

Market Segmentation

By Product Category

·        Glucose Monitoring

·        Infectious Disease Testing

·        Cardiometabolic Testing

·        Molecular Diagnostics

·        Pregnancy & Fertility Testing

·        Hematology and Coagulation

By End-User

·        Hospitals

·        Clinics

·        Diagnostic Centers

·        Home Care Settings

·        Ambulatory Care Centers

By Region

·        North America

·        Europe

·        Asia Pacific

·        Latin America

·        Middle East & Africa

Country-level insights include the United States, Germany, France, Japan, China, India, Brazil, and others.

Competitive Landscape

The market remains competitive, characterized by strategic collaborations, product launches, and R& D investments. Companies are focusing on:

·        Expanding test menus

·        Enhancing molecular capabilities

·        Strengthening global distribution

·        Investing in digital integration and AI-based diagnostics

Comprehensive profiles are available for key players including Sysmex, Abbott Laboratories, Becton Dickinson, Danaher, Quidel Diagnostics, Roche, Thermo Fisher Scientific, Bio-Rad, QIAGEN, bioMérieux, Siemens Healthineers, EKF Diagnostics, Nova Biomedical, and others.

Final Thoughts

The Point of Care Diagnostics Market is undergoing a profound transformation. With projected growth from US$ 50.08 billion in 2024 to US$ 105.22 billion by 2033, the sector reflects not only financial expansion but also a paradigm shift in healthcare delivery.

Rapid diagnostics are redefining clinical workflows, improving emergency response, enabling personalized medicine, and expanding healthcare access globally. As technological innovation continues and sustainability initiatives gain traction, point-of-care diagnostics will play a pivotal role in shaping the future of decentralized and patient-centric healthcare worldwide.